Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sacubitril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME known ✓ | P08473 | 13/20 | 0.77 |
| ▸ | ACE | P12821 | 4/20 | 0.77 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sacubitril SCHEMBL1908525 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL22420467 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL8214132 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL2707112 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18574632 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18059569 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18059568 | 1.00 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL21239958 | 0.99 | MME (0.76) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL21239955 | 0.99 | MME (0.76) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL17746036 | 0.99 | MME (0.76) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 505 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100071-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2024-03-28 | — | — | US | claimed |
| EP-4023218-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-Form Pharma (BE) | 2022-07-06 | — | — | EP | claimed |
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | claimed |
| US-11337972-B2 | Pharmaceutical preparation and use thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2022-05-24 | — | — | US | claimed |
| US-11161803-B2 | Ammonium carboxylate compound, crystalline form, amorphous form and preparation method thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2021-11-02 | — | — | US | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| US-20210052579-A1 | PHARMACEUTICAL PREPARATION AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2021-02-25 | — | — | US | claimed |
| EP-3763373-A1 | PHARMACEUTICAL FORMULATION AND USE THEREOF | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-01-13 | — | — | EP | claimed |
| US-10703731-B2 | Process for the preparation of Trisodium (4- {[1S,3R)-1-([1,1′-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)-(N-petanoyl-N-{[2′-(1H-tetrazol-1-1D-5-yl)[1,1′-biphenyl]-4-yl]methyl}- L-valinate) and its polymorphs thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-07-07 | — | — | US | claimed |
| CN-111265518-A | Composition containing a mixture of biphenyl derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| CN-110713465-A | ARB-NEPi compound, crystal form, preparation method and application | 上海博志研新药物技术有限公司 | 2020-01-21 | — | — | CN | claimed |
| CN-110237072-A | The preparation method of pharmaceutical composition | 武汉朗来科技发展有限公司 | 2019-09-17 | — | — | CN | claimed |
| WO-2019170136-A1 | PHARMACEUTICAL FORMULATION AND USE THEREOF | 武汉朗来科技发展有限公司 | 2019-09-12 | — | — | WO | claimed |
| WO-2019170135-A1 | MEDICINE COMPOSITION PREPARATION METHOD | 武汉朗来科技发展有限公司 | 2019-09-12 | — | — | WO | claimed |
| EP-3524250-A1 | PHARMACEUTICAL COMPOSITION | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2019-08-14 | — | — | EP | claimed |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-14 | — | — | US | claimed |
| US-20190077775-A1 | PROCESS FOR THE PREPARATION OF TRISODIUM (4-{[1S,3R)-1-([1,1'-BIPHENYL]-4-YLMETHYL)-4-ETHOXY-3-METHYL-4-OXOBUTYL]AMINO}-4-OXOBUTANOATE)-(N-PETANOYL-N-{[2'-(1H-TETRAZOL-1-1D-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL}- L-VALINATE) AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2019-03-14 | — | — | US | claimed |
| US-20180311241-A1 | PHARMACEUTICAL SYNERGISTIC COMBINATION | CADILA HEALTHCARE LIMITED (IN) | 2018-11-01 | — | — | US | claimed |
| EP-0555175-A1 | Biaryl substituted 4-amino-butyric acid amides | CIBA-GEIGY AG (CH) | 1993-08-11 | — | — | EP | claimed |
| US-5217996-A | Endopeptidase inhibitors | CIBA-GEIGY CORPORATION (US) | 1993-06-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077775-A1 | PROCESS FOR THE PREPARATION OF TRISODIUM (4-{[1S,3R)-1-([1,1'-BIPHENYL]-4-YLMETHYL)-4-ETHOXY-3-METHYL-4-OXOBUTYL]AMINO}-4-OXOBUTANOATE)-(N-PETANOYL-N-{[2'-(1H-TETRAZOL-1-1D-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL}- L-VALINATE) AND ITS POLYMORPHS THEREOF | TET1, CACNA1S, CYP1B1 | MME 4190/4885ACE 2949/4885MMEL1 1494/4885 |
| US-11161803-B2 | Ammonium carboxylate compound, crystalline form, amorphous form and preparation method thereof | ACMSD, ADSL, AMD1 | MME 3513/4885ACE 110/4885MMEL1 4455/4885 |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | PDE5A, PDE3A, PDE2A | MME 9/4885ACE 34/4885MMEL1 119/4885 |
| US-10703731-B2 | Process for the preparation of Trisodium (4- {[1S,3R)-1-([1,1′-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)-(N-petanoyl-N-{[2′-(1H-tetrazol-1-1D-5-yl)[1,1′-biphenyl]-4-yl]methyl}- L-valinate) and its polymorphs thereof | TET1, CACNA1S, CYP1B1 | MME 4212/4885ACE 2833/4885MMEL1 1506/4885 |
| US-20210052579-A1 | PHARMACEUTICAL PREPARATION AND USE THEREOF | PREP, PEPD, FURIN | MME 4/4885ACE 152/4885MMEL1 256/4885 |
| US-20180311241-A1 | PHARMACEUTICAL SYNERGISTIC COMBINATION | MME, REN, PCSK9 | MME 1/4885ACE 5/4885MMEL1 249/4885 |
| US-11337972-B2 | Pharmaceutical preparation and use thereof | PREP, PEPD, FURIN | MME 4/4885ACE 152/4885MMEL1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.